drugset / Trial / NCT00185640

Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) for Older Patients With Hematologic Malignancies

NCT00185640

Phase 2 Completed 303 enrolled Stanford University
NaSingle-groupOpen-labelTreatment

Summary

To measure how frequently and to what degree a complication of transplant cell acute graft versus host disease (GvHD) occurs.

Timeline

Start
2003-03
Primary completion
2014-04
Completion
2016-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Background ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) Protein / enzyme biologic 1.5 mg/kg Intravenous
Background Cyclosporine Peptide 5 mg/kg Oral
Background Mycophenolate Mofetil Small molecule 15 mg/kg
Background filgrastim Protein / enzyme biologic 5 ug/kg Subcutaneous
Background filgrastim Protein / enzyme biologic 16 ug/kg Subcutaneous

Indications